| Project/Area Number |
16591261
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Ehime University |
|---|
Principal Investigator |
WATANABE Yuji Ehime University, University Hospital, Lecturer, 医学部附属病院, 講師 (20210958)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
河内 寛治 愛媛大学, 医学部, 教授 (90116020)
野村 信福 愛媛大学, 工学部, 助教授 (20263957)
岡部 永年 愛媛大学, 工学部, 教授 (20281181)
青野 宏通 愛媛大学, 工学部, 助教授 (00184052)
猶原 隆 愛媛大学, 工学部, 助教授 (50093935)
|
|---|
| Project Period (FY) |
2004 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥3,700,000 (Direct Cost: ¥3,700,000)
Fiscal Year 2005: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2004: ¥2,700,000 (Direct Cost: ¥2,700,000)
|
|---|
| Keywords | Immunoliposome / Liposome / Induction heating / Magnetic material / Hearctptin / Apoptosis / フェライト |
|---|
| Research Abstract |
Anti-HER2 antibody can induce antitumor responses, and can be used in delivering drugs to HER2-overexressing cancer.
We produced in this study a heat induction procedure which provides hyperthermia using MgFe2O4 nanoparticles that generate heat in an alternating magnetic field. In addition, we constructed anti-HER2 immunoliposomes containing MgFe2O4 nanoparticles, which act as tumor-targeting vehicles, combining anti-HER2 antibody therapy with hyperthermia. The magnetite nanoparticle-loaded anti-HER2 immunoliposomes exerted HER2-mediated antiproliferative effects on SKBr3 breast cancer cells in vitro. Moreover, 60% of magnetite nanoparticles were incorporated into SKBr3, and the cells were then heated at 50℃ under an alternating magnetic field, resulting in strong cytotoxic effects. These results suggest that this novel therapeutic tool is applicable to treatment of HER2-overexpressing cancer. Intravenous administration was not feasible in this series of study. For the next series of study, we plan to research an in vivo model, which comprise an intravenous injection of MgFe2O4 liposome and superselective binding to the SKBr3 cells.
|
